PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
Publication
, Conference
Ranjan, T; Desjardins, A; Peters, KB; Alderson, L; Kirkpatrick, J; Herndon, J; Bailey, L; Sampson, J; Friedman, AH; Friedman, H; Vredenburgh, JJ
Published in: NEURO-ONCOLOGY
October 1, 2012
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
October 1, 2012
Volume
14
Start / End Page
79 / 79
Location
Washington, DC
Publisher
OXFORD UNIV PRESS INC
Conference Name
17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ranjan, T., Desjardins, A., Peters, K. B., Alderson, L., Kirkpatrick, J., Herndon, J., … Vredenburgh, J. J. (2012). PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). In NEURO-ONCOLOGY (Vol. 14, pp. 79–79). Washington, DC: OXFORD UNIV PRESS INC.
Ranjan, Tulika, Annick Desjardins, Katherine B. Peters, Lloyd Alderson, John Kirkpatrick, James Herndon, Leighann Bailey, et al. “PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” In NEURO-ONCOLOGY, 14:79–79. OXFORD UNIV PRESS INC, 2012.
Ranjan T, Desjardins A, Peters KB, Alderson L, Kirkpatrick J, Herndon J, et al. PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2012. p. 79–79.
Ranjan, Tulika, et al. “PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” NEURO-ONCOLOGY, vol. 14, OXFORD UNIV PRESS INC, 2012, pp. 79–79.
Ranjan T, Desjardins A, Peters KB, Alderson L, Kirkpatrick J, Herndon J, Bailey L, Sampson J, Friedman AH, Friedman H, Vredenburgh JJ. PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2012. p. 79–79.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
October 1, 2012
Volume
14
Start / End Page
79 / 79
Location
Washington, DC
Publisher
OXFORD UNIV PRESS INC
Conference Name
17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences